These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29045551)

  • 1. Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.
    Jain S; Lyons CA; Walker SM; McQuaid S; Hynes SO; Mitchell DM; Pang B; Logan GE; McCavigan AM; O'Rourke D; McArt DG; McDade SS; Mills IG; Prise KM; Knight LA; Steele CJ; Medlow PW; Berge V; Katz B; Loblaw DA; Harkin DP; James JA; O'Sullivan JM; Kennedy RD; Waugh DJ
    Ann Oncol; 2018 Jan; 29(1):215-222. PubMed ID: 29045551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy.
    Van der Kwast T; Al Daoud N; Collette L; Sykes J; Thoms J; Milosevic M; Bristow RG; Van Tienhoven G; Warde P; Mirimanoff RO; Bolla M
    Eur J Cancer; 2012 Jun; 48(9):1318-25. PubMed ID: 22405699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy.
    Peng LC; Narang AK; Gergis C; Radwan NA; Han P; Marciscano AE; Robertson SP; He P; Trieu J; Ram AN; McNutt TR; Griffith E; DeWeese TA; Honig S; Singh H; Greco SC; Tran PT; Deville C; DeWeese TL; Song DY
    Urol Oncol; 2018 Jun; 36(6):309.e7-309.e14. PubMed ID: 29551548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
    Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
    PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
    Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
    BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
    Cooperberg MR; Broering JM; Carroll PR
    J Natl Cancer Inst; 2009 Jun; 101(12):878-87. PubMed ID: 19509351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
    Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?
    Saad A; Goldstein J; Lawrence YR; Spieler B; Leibowitz-Amit R; Berger R; Davidson T; Urban D; Tsang L; Alezra D; Weiss I; Symon Z
    Radiat Oncol; 2017 Jan; 12(1):5. PubMed ID: 28061904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer.
    Narang AK; Trieu J; Radwan N; Ram A; Robertson SP; He P; Gergis C; Griffith E; Singh H; DeWeese TA; Honig S; Annadanam A; Greco S; DeVille C; McNutt T; DeWeese TL; Song DY; Tran PT
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):203-209. PubMed ID: 28094250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
    Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
    J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
    Alves de Inda M; van Strijp D; den Biezen-Timmermans E; van Brussel A; Wrobel J; van Zon H; Vos P; Baillie GS; Tennstedt P; Schlomm T; Houslay MD; Bangma C; Hoffmann R
    Eur Urol Focus; 2018 Apr; 4(3):376-384. PubMed ID: 28753810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
    Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
    Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
    Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S
    Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.
    Budäus L; Isbarn H; Tennstedt P; Salomon G; Schlomm T; Steuber T; Haese A; Chun F; Fisch M; Michl U; Heinzer H; Huland H; Graefen M
    BJU Int; 2012 Dec; 110(11):1714-20. PubMed ID: 22520619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.